The National Cancer Institute-Children’s Oncology Group Pediatric Molecular Analysis for Therapy Choice (MATCH) trial also investigated the efficacy of tazemetostat for SMARCB1/INI1-deficient or EZH2-mutated refractory solid tumors, brain tumors, lymphoma, or histiocytic disorders in a biomarker selected population, including those with loss of function of SMARCA1 or SMARCA4, or hotspot EZH2 mutations. This evidence concerns the gene SMARCA1 and brain neoplasm.